Pituitary Pars Intermedia Dysfunction in Horses

Professional summary: A practical reference on recognising, testing and monitoring equine pituitary pars intermedia dysfunction, including laminitis risk.

Clinical overview

Pituitary pars intermedia dysfunction is a neurodegenerative endocrine disorder of older equids. Excess production of pituitary peptides contributes to characteristic clinical signs and increased susceptibility to laminitis and infection.

Use the reference as a structured starting point. The patient's species, age, breed, physiologic state, disease duration and previous treatment can substantially change the diagnostic and management pathway. Where the presentation is atypical, return to first principles and reconsider the problem list before adding therapy.

Clinical presentation

Hypertrichosis or delayed coat shedding is highly suggestive. Other signs include muscle wasting, abnormal fat distribution, lethargy, polyuria, polydipsia, recurrent infection, sweating abnormalities and laminitis. Early disease may be subtle.

Severity should be judged from function and trend rather than from one isolated sign. Record onset, progression, triggers, appetite, drinking, elimination, activity and sleep. Videos or home observations can reveal abnormalities that are absent in the consulting room, particularly for intermittent lameness, coughing, pain and behavioural change.

Diagnostic approach

Basal ACTH testing is commonly used and must be interpreted with seasonally adjusted reference intervals. Dynamic testing may be useful in equivocal cases. Stress, pain and concurrent illness can influence results. Evaluate insulin regulation because PPID and insulin dysregulation may coexist.

Choose tests that answer a defined clinical question. Confirm sample quality and interpret results against hydration, stress, recent medication and pre-test probability. Repeating a focused examination or measurement after stabilisation is often more informative than ordering a broad panel without a plan for how the result will alter management.

Treatment and management

Pergolide is the principal medical treatment. Begin and adjust therapy according to clinical response and repeat testing. Reduced appetite may occur after initiation. Management also includes dental care, parasite control, vaccination, body-condition management, clipping when needed and aggressive laminitis prevention.

Set immediate and longer-term goals, then reassess whether each intervention is achieving them. Minimise unnecessary polypharmacy and document the reason for every medicine, procedure and restriction. Where treatment carries important renal, hepatic, gastrointestinal, cardiovascular or behavioural risk, establish a monitoring plan before discharge.

Monitoring and reassessment

Assess coat, energy, muscle mass, drinking, infection frequency and hoof health. Repeat ACTH testing at an appropriate interval and season. Monitor insulin where laminitis risk is relevant.

Define what improvement should look like and when it should occur. A useful monitoring plan names the variable, method, frequency and threshold for action. Failure to improve within the expected window, recurrence after initial response or emergence of new systemic signs should trigger diagnostic review rather than automatic repetition of the same treatment.

Prognosis

PPID is lifelong but often manageable. Early identification and control of laminitis risk substantially improve welfare and longevity.

Prognosis should be presented as a range and updated as response becomes clear. Separate survival, functional recovery, recurrence risk, long-term medication burden and quality of life. Discuss factors that can be modified, such as body condition, adherence and timely rechecks, alongside factors that cannot.

Clinical priorities

Begin with patient stability, pain and welfare. Urgent respiratory compromise, circulatory shock, severe neurological deterioration, inability to urinate, uncontrolled haemorrhage or rapidly progressive abdominal disease should be addressed before a complete elective work-up. The order of investigation should be adapted to the patient's tolerance and the likelihood that a delay will change outcome.

Differential diagnoses and concurrent disease

Avoid anchoring on the first plausible diagnosis. Build a prioritised differential list from signalment, time course, examination and objective tests. Concurrent disease can alter both clinical signs and treatment tolerance. Medication history, nutrition, reproductive status, travel, environment and previous response to therapy should be reviewed because each may expose an alternative explanation or a factor that needs treatment in parallel.

Communication with the owner or carer

Explain the working diagnosis, degree of certainty, immediate priorities and expected decision points. Provide clear instructions on medication administration, activity, feeding, monitoring and emergency warning signs. Where several treatment pathways are reasonable, discuss expected benefits, limitations, cost, follow-up burden and the consequences of delayed escalation. Written plans reduce misunderstanding and support continuity between clinicians.

Prevention and long-term care

Prevention depends on the underlying disorder and may include body-condition management, appropriate exercise, environmental modification, preventive healthcare, early screening and prompt review of recurrent signs. Long-term plans should be practical for the household or yard and reviewed when circumstances change. A technically ideal plan that cannot be followed consistently is less useful than a safe, prioritised plan with measurable goals.

Evidence and clinical judgement

Published guidelines and consensus statements provide a framework but do not replace examination of the individual patient. Recommendations may differ between countries because of drug licensing, antimicrobial policy, available diagnostics and referral access. Use current product information, local regulations and specialist advice where needed. This reference deliberately avoids fixed drug doses because dosing depends on species, weight, formulation, route, organ function and the complete clinical context.

Key clinical points

• Stabilise urgent threats before completing the full diagnostic pathway.
• Use history, examination and objective findings together; avoid relying on one test.
• Select treatment according to severity, patient factors and the underlying cause.
• Reassess response using defined clinical and laboratory goals.
• Escalate promptly when deterioration, treatment intolerance or an unexpected course develops.

Frequently asked clinical questions

When should pituitary pars intermedia dysfunction in horses be treated as urgent?

Urgency is determined by physiologic stability, speed of progression, pain, loss of normal function and the risk of irreversible injury. Respiratory distress, collapse, shock, severe or escalating pain, inability to pass urine, rapidly worsening neurological deficits, repeated unproductive retching, marked abdominal distension or a sudden change in mentation require immediate assessment. A patient can have a serious disorder before routine laboratory values become markedly abnormal, so triage should begin with the patient rather than the test result.

What is the most common reason for an incomplete response?

Common reasons include an incorrect or incomplete diagnosis, an untreated concurrent disorder, insufficient duration, poor administration technique, unrealistic activity or feeding instructions, and failure to reassess after the first intervention. In chronic disease, control may fluctuate even when the original diagnosis is correct. Review adherence respectfully, confirm that the owner can carry out the plan, and repeat focused examination or testing before simply escalating medication.

How should follow-up be planned?

Follow-up should be matched to the expected pace of change and treatment risk. Unstable or recently discharged patients may need reassessment within hours or days, whereas stable chronic disease may be reviewed at longer intervals. Give owners measurable home observations such as respiratory rate, appetite, water intake, urine output, body weight, pain score, mobility or episode frequency. State exactly which change should trigger earlier contact.

Can a standard protocol be used for every patient?

No. Protocols improve consistency, but they must be adapted for species, size, age, pregnancy, temperament, organ function, concurrent medicines, referral availability and owner circumstances. Treatment that is licensed or routine in one country may not be appropriate in another. Record the clinical reasoning behind departures from a protocol and use the least complex plan that safely meets the patient’s needs.

References and further reading

1. Equine Endocrinology Group. Recommendations for the Diagnosis and Management of PPID.
2. Merck Veterinary Manual. Pituitary Pars Intermedia Dysfunction in Horses.
3. AAEP resources on PPID and laminitis.

Last editorial preparation: August 2026. Verify current guidelines, medicines and local regulations before clinical use.